 In the previous observation studyCHINA ONCOLOGY 2013 Vol.23 No.12 p980, In study arm A, the patients received three-step chemotherapy after primary debulking surgery, step one with paclitaxel plus carboplatin TC regimen, every 3 weeks for 6 to 8 cycles; step two with etoposide plus cyclophosphamide, every 4 weeks for 6 cycles; step three with carboplatin plus cyclophosphamide every eight weeks for six cycles. In control arm B, investigators retrospectively analysed 51 cases withIIIC-IVstage ovarian cancer, who had completely response after standard chemotherapy with six to eight cycles of TC after primary surgery during 2007. Investigators compared the 5-year DFS between the two arms. Results: The 5-year DFS of 15 cases in arm A was 801215, which was signiifcantly higher than that of arm B 5.9, 351, P0.01. Therefore we start this randomized open control clinic trial to evaluated the effect of ACTS on overall survival and its safety. 